Floatz logo

URACIL RIBOSIDE

Lipoatrophy

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 2/3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lipoatrophy cohort.

Asset / SponsorPhaseRating
Efavirenz
Juan A. Arnaiz
Phase 4A
Lamivudine
Thomas Benfield
Phase 4BBB
Abacavir
Kirby Institute
Phase 4BBB
ZIDOVUDINE
Kirby Institute
Phase 4BBB
PRAVASTATIN
Kirby Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

URACIL RIBOSIDE is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
69 / 100
View asset →
metabolic diseaseDormant
B
Indicative ·
57 / 100
View asset →
nutritional deficiency diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →